Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Cerevel surges on positive data for CVL-231 in schizophrenia trial, start of public offering

firstwordpharmaJune 30, 2021

Tag: Cerevel , CVL-231 , PANSS

PharmaSources Customer Service